Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Key Takeaways Fresenius Medical sees growth from FME25 savings, value-based care and the 5008X CAREsystem rollout.FMS' Value-Based Care hit EUR 2B in revenues in 2025, with 42% Q4 organic growth and breakeven profit.FMS faces a EUR 150-200M headwind from the TDAPA phase-out, flat U.S. volumes and China regulatory drag.Fresenius Medical Care AG & Co. (FMS) is well-positioned for growth, backed by strong profitability improvements from its FME25+ transformation program and growing momentum in value-based care ...